

DAFTAR PUSTAKA

- Abbas, E.E., Afioni, N., Al Wakeel, J., Bakr, M.A., Dham, R., Donia, A., *et al.*, 2004. The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis. *Transplant. Proc.* 36, 1805–1811. <https://doi.org/10.1016/j.transproceed.2004.07.038>
- Abdel-Kader, K., Unruh, M.L., Weisbord, S.D., 2009. Symptom Burden, Depression, and Quality of Life in Chronic and End-Stage Kidney Disease. *Clin. J. Am. Soc. Nephrol.* 4, 1057–1064. <https://doi.org/10.2215/CJN.00430109>
- Acaray, A., Pinar, R., 2005. Quality of Life in Turkish Haemodialysis Patients. *Int. Urol. Nephrol.* 37, 595–602. <https://doi.org/10.1007/s11255-005-0397-8>
- Acaster, S., Dickerhoof, R., DeBusk, K., Bernard, K., Strauss, W., Allen, L.F., 2015. Qualitative and quantitative validation of the FACIT-fatigue scale in iron deficiency anemia. *Health Qual. Life Outcomes* 13. <https://doi.org/10.1186/s12955-015-0257-x>
- Alchusna, A.R.A., Susilaningrum, D., 2012. Pengukuran Tingkat Efisiensi Pelayanan Unit Hemodialisis di Rumah Sakit H1 dan H2 dengan Data Envelopment Analysis (DEA) Abstrak—Unit hemodialisis merupakan salah satu bagian ben-tuk layanan kesehatan dari suatu rumah sakit yang mahal dan sangat penting. *J. Sains Dan Seni ITS* 1, D219–D223.
- Alsalmiy, N., Awaisu, A., 2014. Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review. *Int. J. Clin. Pharm.* 36, 1115–1125. <https://doi.org/10.1007/s11096-014-0023-x>
- Al-Shohaib, S., Shaker, D.S., Ghaedi, B.B., Alyarim, M., Emara, S., Behairy, M., 2010. The Hematopoietic Effect of Epotin (Recombinant Human Erythropoietin- α) on Maintenance Hemodialysis End-Stage Kidney Disease Patients. *Transplant. Proc.* 42, 753–759. <https://doi.org/10.1016/j.transproceed.2010.02.056>
- Andayani, T.M., 2013. *Farmakoekonemi*. Bursa Ilmu, 73-94.
- Askes, P., 2012. *INDONESIAN RENAL REGISTRY* 40.
- Ayoub, A.M., Hijjazi, K.H., 2013. Quality of life in dialysis patients from the United Arab Emirates. *J. Fam. Community Med.* 20, 106.
- Beddhu, S., Bruns, F.J., Saul, M., Seddon, P., Zeidel, M.L., 2000. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. *Am. J. Med.* 108, 609–613. [https://doi.org/10.1016/S0002-9343\(00\)00371-5](https://doi.org/10.1016/S0002-9343(00)00371-5)
- Besarab, A., Bolton, W.K., Browne, J.K., Egrie, J.C., Nissenson, A.R., Okamoto, *et al.*, 1998. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. *N. Engl. J. Med.* 339, 584–590.

- Besarab, A., Levin, A., 2000. Defining a renal anemia management period. *Am. J. Kidney Dis.* 36, S13–S23. <https://doi.org/10.1053/ajkd.2000.19927>
- Beusterien, M., Nissenson, R., Port, K., Ware, E., 1996. The Effects of Recombinant Human Erythropoietin on Functional Health and Well-Being in Chronic Dialysis Patients. *J. Am. Soc. Nephrol.* 11.
- Bia, M., Adey, D.B., Bloom, R.D., Chan, L., Kulkarni, S., Tomlanovich, S., 2010. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. *Am. J. Kidney Dis.* 56, 189–218.
- Bohlke, M., Nunes, D.L., Marini, S.S., Kitamura, C., Andrade, M., Von-Gysel, M.P.O., 2008. Predictors of quality of life among patients on dialysis in southern Brazil. *Sao Paulo Med. J.* 126, 252–256.
- Bootman, J.L., Townsend, R.J., McGhan, W.F. (Eds.), 2005. *Principles of pharmacoeconomics*, 3rd ed. ed. Harvey Whitney Books Co, Cincinnati, OH.
- Buckley, M.S., Kane-Gill, S.L., Patel, S.A., 2013. Clinical and Economic Evaluation of an Evidence-Based Institutional Epoetin-Utilization Management Program. *Clin. Ther.* 35, 294–302. <https://doi.org/10.1016/j.clinthera.2013.02.002>
- Carrera, F., Lok, C.E., de Francisco, A., Locatelli, F., Mann, J.F.E., Canaud, B., *et al.*, 2010. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. *Nephrol. Dial. Transplant.* 25, 4009–4017. <https://doi.org/10.1093/ndt/gfq305>
- Cavanaugh, K.L., 2007. Diabetes management issues for patients with chronic kidney disease. *Clin. Diabetes* 25, 90–97.
- Cella, D., Lai, J.-S., Chang, C.-H., Peterman, A., Slavin, M., 2002. Fatigue in cancer patients compared with fatigue in the general United States population. *Cancer* 94, 528–538. <https://doi.org/10.1002/cncr.10245>
- Cella, D., Yount, S., Sorensen, M., Chartash, E., Sengupta, N., Grober, J., 2005. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. *J. Rheumatol.* 32, 811–819.
- Chandran, V., Bhella, S., Schentag, C., Gladman, D.D., 2007. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. *Ann. Rheum. Dis.* 66, 936–939. <https://doi.org/10.1136/ard.2006.065763>
- Chowdhury, P.P., Balluz, L., Strine, T.W., 2008. Health-related quality of life among minority populations in the United States, BRFSS 2001–2002. *Ethn Dis* 18, 483–487.
- Collister, D., Komenda, P., Hiebert, B., Gunasekara, R., Xu, Y., Eng, F., *et al.*, 2016. The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis. *Ann. Intern. Med.* 164, 472–478. <https://doi.org/10.7326/M15-1839>

- Costanza, R., Fisher, B., Ali, S., Beer, C., Bond, L., Boumans, R., *et al.*, 2007. Quality of life: An approach integrating opportunities, human needs, and subjective well-being. *Ecol. Econ.* 61, 267–276. <https://doi.org/10.1016/j.ecolecon.2006.02.023>
- Darmeizar, 2016. "Ada sekitar 12,5 persen dari total penduduk Indonesia atau sebanyak 25-30 juta orang mengalami penurunan fungsi ginjal". <https://gaya.tempo.co/read/742064/30-juta-penduduk-indonesia-alami-penurunan-fungsi-ginjal/full&view=ok>
- de Goeij, M.C.M., Meuleman, Y., van Dijk, S., Grootendorst, D.C., Dekker, F.W., Halbesma, N., for the PREPARE-2 Study Group, 2014. Haemoglobin levels and health-related quality of life in young and elderly patients on specialized predialysis care. *Nephrol. Dial. Transplant.* 29, 1391–1398. <https://doi.org/10.1093/ndt/gft533>
- DiPiro, J.T., 2014. *Pharmacotherapy: a pathophysiologic approach*, 9 ed. McGraw-Hill Education / Medical, New York.
- Drüeke, T.B., Locatelli, F., Clyne, N., Eckardt, K.-U., Macdougall, I.C., Tsakiris, D., *et al.*, 2006. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *N. Engl. J. Med.* 355, 2071–2084.
- Elliott, S., Pham, E., Macdougall, I.C., 2008. Erythropoietins: A common mechanism of action. *Exp. Hematol.* 36, 1573–1584. <https://doi.org/10.1016/j.exphem.2008.08.003>
- Escudero-Vilaplana, V., Mart?nez-Nieto, C., L?pez-G?mez, J.M., Vega-Mart?nez, A., Bell?n-Cano, J.M., Sanjurjo-S?ez, M., 2013. Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis. *Int. J. Clin. Pharm.* 35, 463–468. <https://doi.org/10.1007/s11096-013-9774-z>
- Fayers, P.M., Hays, R.D. (Eds.), 2004. *Assessing quality of life in clinical trials: methods and practice*, 2nd ed. ed. Oxford University Press, Oxford ; New York.
- Fishbane, S., Besarab, A., 2007. Mechanism of Increased Mortality Risk with Erythropoietin Treatment to Higher Hemoglobin Targets. *Clin. J. Am. Soc. Nephrol.* 2, 1274–1282. <https://doi.org/10.2215/CJN.02380607>
- Georgios, T., 2015. Assessment of Quality of Life and Fatigue among Haemodialysis Patients. *Am. J. Nurs. Sci.* 4, 66. <https://doi.org/10.11648/j.ajns.s.2015040201.22>
- Guerra-Guerrero, V., Sanhueza-Alvarado, O., Cáceres-Espina, M., 2012. Qualidade de vida de pessoas em hemodiálise crônica: relação com variáveis sociodemográficas, médico-clínicas e de laboratório. *Rev. Lat. Am. Enfermagem* 20, 838–846.
- Halstenson, C.E., Macres, M., Katz, S.A., Schnieders, J.R., Watanabe, M., Sobota, J.T., Abraham, P.A., 1991. Comparative pharmacokinetics and

- pharmacodynamics of epoetin alfa and epoetin beta. *Clin. Pharmacol. Ther.* 50, 702–712. <https://doi.org/10.1038/clpt.1991.210>
- Hays, R.D., Kallich, J.D., Mapes, D.L., Coons, S.J., Carter, W.B., 1994. Development of the Kidney Disease Quality of Life (KDQOLTM) Instrument. *Qual. Life Res.* 3, 329–338. <https://doi.org/10.1007/BF00451725>
- Herfindal, E.T., Gourley, D.R. (Eds.), 2000. Textbook of therapeutics: drug and disease management, 7th ed. ed. Lippincott Williams & Wilkins, Philadelphia.
- Himmelfarb, J., Ikizler, T.A., 2010. Hemodialysis. *N. Engl. J. Med.* 363, 1833–1845. <https://doi.org/10.1056/NEJMra0902710>
- Hutchinson, F.N., Jones, W.J., 1997. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease. *Am. J. Kidney Dis. Off. J. Natl. Kidney Found.* 29, 651–657.
- Icks, A., Haastert, B., Gandjour, A., Chernyak, N., Rathmann, W., Giani, G., Rump, L.C., Trapp, R., Koch, M., 2010. Costs of dialysis--a regional population-based analysis. *Nephrol. Dial. Transplant.* 25, 1647–1652. <https://doi.org/10.1093/ndt/gfp672>
- INDONESIAN RENAL REGISTRY, 2015. Report of Indonesian Renal Registry.
- Jamison, D.T., Breman, J.G., Measham, A.R., Alleyne, G., Claeson, M., Evans, D.B., Jha, P., Mills, A., Musgrove, P., 2006. Cost-effectiveness analysis.
- Jha, V., 2004. End-Stage Renal Care in Developing Countries: The India Experience. *Ren. Fail.* 26, 201–208. <https://doi.org/10.1081/JDI-120039516>
- Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., *et al.*, 2013. Chronic kidney disease: global dimension and perspectives. *The Lancet* 382, 260–272.
- Jhamb, M., Weisbord, S.D., Steel, J.L., Unruh, M., 2008. Fatigue in Patients Receiving Maintenance Dialysis: A Review of Definitions, Measures, and Contributing Factors. *Am. J. Kidney Dis.* 52, 353–365. <https://doi.org/10.1053/j.ajkd.2008.05.005>
- Johansen, K.L., Chertow, G.M., 2007. Chronic Kidney Disease Mineral Bone Disorder and Health-Related Quality of Life Among Incident End-Stage Renal-Disease Patients. *J. Ren. Nutr.* 17, 305–313. <https://doi.org/10.1053/j.jrn.2007.06.005>
- Jones, M., Ibels, L., Schenkel, B., Zagari, M., 2004. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. *Kidney Int.* 65, 757–767.
- Kalantar-Zadeh, K., Kopple, J.D., Block, G., Humphreys, M.H., 2001. Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. *J. Am. Soc. Nephrol.* 12, 2797–2806.
- KDIGO-Anemia-GL-Suppl-Tables-August-2012.pdf, n.d.
- Kementerian Kesehatan RI, 2018. Riset Kesehatan Dasar, Badan Penelitian dan Pengembangan Kesehatan Kemenkes RI.

- Kementerian Kesehatan RI, 2014. Peraturan Menteri Kesehatan No. 59 tahun 2014 tentang standar tarif pelayanan kesehatan dalam penyelenggaraan program jaminan kesehatan.
- Kimmel, P.L., 2001. Psychosocial factors in dialysis patients. *Kidney Int.* 59, 1599–1613.
- Lai, J.-S., Beaumont, J.L., Ogale, S., Brunetta, P., Cella, D., 2011. Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial. *J. Rheumatol.* 38, 672–679. <https://doi.org/10.3899/jrheum.100799>
- Lee, K.A., Hicks, G., Nino-Murcia, G., 1991. Validity and reliability of a scale to assess fatigue. *Psychiatry Res.* 36, 291–298.
- Levey, A.S., Coresh, J., Balk, E., Kausz, A.T., Levin, A., Steffes, M.W., *et al.*, 2003. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann. Intern. Med.* 139, 137–147.
- Levin, A., Thompson, C.R., Ethier, J., Carlisle, E.J.F., Tobe, S., Mendelssohn, D., *et al.*, 1999. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. *Am. J. Kidney Dis.* 34, 125–134. [https://doi.org/10.1016/S0272-6386\(99\)70118-6](https://doi.org/10.1016/S0272-6386(99)70118-6)
- Levin, N.W., Lazarus, J.M., Nissenson, A.R., 1993. National Cooperative rHu Erythropoietin Study in Patients With Chronic Renal Failure? An Interim Report. *Am. J. Kidney Dis.* 22, 3–12. [https://doi.org/10.1016/0272-6386\(93\)70176-Y](https://doi.org/10.1016/0272-6386(93)70176-Y)
- Li, L., 1996. End-stage renal disease in China. *Kidney Int.* 49, 287–301.
- Li, P.K., Chow, K.M., 2001. The cost barrier to peritoneal dialysis in the developing world—an Asian perspective. *Perit. Dial. Int.* 21, S307–S313.
- Lima, M.G., Barros, M.B. de A., César, C.L.G., Goldbaum, M., Carandina, L., Ciconelli, R.M., 2009. Health related quality of life among the elderly: a population-based study using SF-36 survey. *Cad. Saude Publica* 25, 2159–2167.
- Liu, H.E., 2006. Fatigue and associated factors in hemodialysis patients in Taiwan. *Res. Nurs. Health* 29, 40–50. <https://doi.org/10.1002/nur.20109>
- Locatelli, F., Del Vecchio, L., 2011. Erythropoiesis-Stimulating Agents in Renal Medicine. *The Oncologist* 16, 19–24. <https://doi.org/10.1634/theoncologist.2011-S3-19>
- Loughnan, A., Ali, G.R., Abeygunasekara, S.C., 2011. Comparison of the Therapeutic Efficacy of Epoetin Beta and Epoetin Alfa in Maintenance Phase Hemodialysis Patients. *Ren. Fail.* 33, 373–375. <https://doi.org/10.3109/0886022X.2011.559675>
- Mani, M.K., 1993. Chronic renal failure in India. *Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc.* 8, 684–689; discussion 683.
- Mapes, D.L., Lopes, A.A., Satayathum, S., Mccullough, K.P., Goodkin, D.A., Locatelli, F., *et al.*, 2003. Health-related quality of life as a predictor of

- mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Kidney Int.* 64, 339–349.
- McPhee, S.J., 2000. *Pathophysiology of disease: an introduction to clinical medicine*. Lange Medical Books/McGraw-Hill, New York.
- Memoli, B., Libetta, C., Rampino, T., Dal Canton, A., Conte, G., Scala, G., *et al.*, 1992. Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells. *Kidney Int.* 42, 320–326.
- Naci, H., de Lissoyoy, G., Hollenbeak, C., Custer, B., Hofmann, A., McClellan, W., *et al.*, 2012. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis. *J. Med. Econ.* 15, 293–304. <https://doi.org/10.3111/13696998.2011.644407>
- Ohashi, N., Sakao, Y., Yasuda, H., Kato, A., Fujigaki, Y., 2012. Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease. *Int. J. Nephrol. Renov. Dis.* 5, 53.
- Palmer, S.C., Saglimbene, V., Mavridis, D., Salanti, G., Craig, J.C., Tonelli, M., *et al.*, 2014. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis, in: *The Cochrane Collaboration* (Ed.), *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, Chichester, UK. <https://doi.org/10.1002/14651858.CD010590.pub2>
- Pradelli, L., Wertheimer, A., 2012. *Pharmacoeconomics: principles and practice*.
- Rao, C., Adair, T., Bain, C., Doi, S.A., 2011. Mortality from diabetic renal disease: a hidden epidemic. *Eur. J. Public Health* 22, 280–284.
- Ream, E., Richardson, A., 1996. Fatigue: a concept analysis. *Int. J. Nurs. Stud.* 33, 519–529. [https://doi.org/10.1016/0020-7489\(96\)00004-1](https://doi.org/10.1016/0020-7489(96)00004-1)
- Remuzzi, G., Schieppati, A., Ruggenti, P., 2002. Nephropathy in Patients with Type 2 Diabetes. *N. Engl. J. Med.* 346, 1145–1151. <https://doi.org/10.1056/NEJMcp011773>
- Roggeri, D.P., Roggeri, A., Salomone, M., 2014. Chronic Kidney Disease: Evolution of Healthcare Costs and Resource Consumption from Predialysis to Dialysis in Piedmont Region, Italy. *Adv. Nephrol.* 2014, 1–6. <https://doi.org/10.1155/2014/680737>
- Ross, S.D., Fahrback, K., Frame, D., Scheye, R., Connelly, J.E., Glaspy, J., 2003. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. *Clin. Ther.* 25, 1786–1805.
- Saglimbene, V., Palmer, S.C., Craig, J.C., Ruospo, M., Nicolucci, A., Tonelli, M., *et al.*, 2017. Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial. *PLOS ONE* 12, e0172735. <https://doi.org/10.1371/journal.pone.0172735>
- Schiffli, H., Lang, S.M., 2006. Folic acid deficiency modifies the haematopoietic response to recombinant human erythropoietin in maintenance dialysis

- patients. *Nephrol. Dial. Transplant.* 21, 133–137.
<https://doi.org/10.1093/ndt/gfi086>
- Schwartz, J., Winters, J.L., Padmanabhan, A., Balogun, R.A., Delaney, M., Linenberger, M.L., *et al.*, 2013. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. *J. Clin. Apheresis* 28, 145–284.
- Seica, A., Segall, L., Verzan, C., Vaduva, N., Madincea, M., Rusoiu, S., *et al.*, 2008. Factors affecting the quality of life of haemodialysis patients from Romania: a multicentric study. *Nephrol. Dial. Transplant.* 24, 626–629.
<https://doi.org/10.1093/ndt/gfn506>
- Septiwi, C., 2011. Hubungan antara adekuasi hemodialisis dengan kualitas hidup pasien hemodialisis di unit hemodialisis RS Prof. Dr. Margono Soekarjo Purwokerto 121.
- Signorovitch, J., Brainsky, A., Grotzinger, K.M., 2011. Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia. *Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil.* 20, 1737–1744.
<https://doi.org/10.1007/s11136-011-9912-9>
- Singh, A.K., Szczech, L., Tang, K.L., Barnhart, H., Sapp, S., Wolfson, M., *et al.*, 2006. Correction of anemia with epoetin alfa in chronic kidney disease. *N. Engl. J. Med.* 355, 2085–2098.
- Siregar, S., 2013. Statistik Parametrik untuk Penelitian Kuantitatif, Bumi Aksara, Jakarta.
- Smith, D.H., 2004. Cost of Medical Care for Chronic Kidney Disease and Comorbidity among Enrollees in a Large HMO Population. *J. Am. Soc. Nephrol.* 15, 1300–1306.
<https://doi.org/10.1097/01.ASN.0000125670.64996.BB>
- Somvanshi, S., Khan, N.Z., Ahmad, M., 2012. Anemia in chronic kidney disease patients. *Clin. Queries Nephrol.* 1, 198–204.
<https://doi.org/10.1016/j.cqn.2012.06.003>
- Sörgel, F., Thyroff-Friesinger, U., Vetter, A., Vens-Cappell, B., Kinzig, M., 2009. Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration. *Int. J. Clin. Pharmacol. Ther.* 47, 391–401.
- Srinivasan, R., Fredy, I.C., Chandrashekar, S., Saravanan, J., Mohanta, G.P., Manna, P.K., 2016. Assessment of erythropoietin for treatment of anemia in chronic kidney failure- ESRD patients. *Biomed. Pharmacother.* 82, 44–48.
<https://doi.org/10.1016/j.biopha.2016.04.041>
- Storring, P.L., Tiplady, R.J., Das, R.E.G., Stenning, B.E., Lamikanra, A., Rafferty, B., Lee, J., 1998. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. *Br. J. Haematol.* 11.

- Strippoli, G.F., 2010. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (CE DOSE) trial protocol. *Trials* 11, 70.
- Taler, S.J., Agarwal, R., Bakris, G.L., Flynn, J.T., Nilsson, P.M., Rahman, M., *et al.*, 2013. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. *Am. J. Kidney Dis.* 62, 201–213.
- Thaweethamcharoen, T., Sakulbumrungsil, R., Nopmaneejumruslers, C., Vasuvattakul, S., 2014. Cost-Utility Analysis of Erythropoietin for Anemia Treatment in Thai End-Stage Renal Disease Patients with Hemodialysis. *Value Health Reg. Issues* 3, 44–49. <https://doi.org/10.1016/j.vhri.2014.01.001>
- Tinsley, A., Macklin, E.A., Korzenik, J.R., Sands, B.E., 2011. Validation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) in patients with inflammatory bowel disease: Validation of a fatigue scale in IBD. *Aliment. Pharmacol. Ther.* 34, 1328–1336. <https://doi.org/10.1111/j.1365-2036.2011.04871.x>
- Tomasello, S., 2008. Secondary hyperparathyroidism and chronic kidney disease. *Diabetes Spectr.* 21, 19–25.
- Tonelli, M., Winkelmayer, W.C., Jindal, K.K., Owen, W.F., Manns, B.J., 2003. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. *Kidney Int.* 64, 295–304.
- TRASK, L.S., 2011. Chapter 1. Pharmacoeconomics: Principles, Methods, and Applications, in: DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M. (Eds.), *Pharmacotherapy: A Pathophysiologic Approach*, 8e. The McGraw-Hill Companies, New York, NY.
- Tsubakihara, Y., Nishi, S., Akiba, T., Hirakata, H., Iseki, K., Kubota, M., *et al.*, 2010. 2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease: 2009 JDST Anemia Guidelines. *Ther. Apher. Dial.* 14, 240–275. <https://doi.org/10.1111/j.1744-9987.2010.00836.x>
- Van, K.N., Duangpaeng, S., Deenan, A., Bonner, A., 2012. Examining the health related quality of life of people with end stage kidney disease living in Hanoi, Vietnam. *Ren. Soc. Australas. J.* 8, 140–145.
- Vanrenterghem, Y., Bárány, P., Mann, J.F.E., Kerr, P.G., Wilson, J., Baker, N.F., *et al.*, 2002. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. *Kidney Int.* 62, 2167–2175. <https://doi.org/10.1046/j.1523-1755.2002.00657.x>
- Ventegodt, S., Merrick, J., Andersen, N.J., 2003. Quality of Life Theory II. Quality of Life as the Realization of Life Potential: A Biological Theory of Human Being. *Sci. World J.* 3, 1041–1049. <https://doi.org/10.1100/tsw.2003.83>
- Walters, S.J., 2009. Quality of life outcomes in clinical trials and health-care evaluation: a practical guide to analysis and interpretation, *Statistics in practice*. John Wiley & Sons, Chichester, U.K.

- Wang, L.-J., Chen, C.-K., n.d. The Psychological Impact of Hemodialysis on Patients with Chronic Renal Failure 21.
- Webster, K., Cella, D., Yost, K., 2003. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. *Health Qual. Life Outcomes* 1, 79.
- Wells, B.G., DiPiro, J.T., Matzke, G.R., Posey, L.M., Schwinghammer, T.L., 2009. *Pharmacotherapy Handbook* (7th Edition). McGraw-Hill Professional Publishing, New York, USA.
- Wilson, J., Yao, G.L., Raftery, J., Bohlius, J., Brunskill, S., Sandercock, J., *et al.*, 2007. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment.
- Yang, F., Griva, K., Lau, T., Vathsala, A., Lee, E., Ng, H.J., *et al.*, 2015. Health-related quality of life of Asian patients with end-stage renal disease (ESRD) in Singapore. *Qual. Life Res.* 24, 2163–2171. <https://doi.org/10.1007/s11136-015-0964-0>
- Yarnoff, B.O., Hoerger, T.J., Simpson, S.A., Pavkov, M.E., Burrows, N.R., Shrestha, S.S., *et al.*, 2016. The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease. *PLOS ONE* 11, e0157323. <https://doi.org/10.1371/journal.pone.0157323>
- Yellen, S.B., Cella, D.F., Webster, K., Blendowski, C., Kaplan, E., 1997. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. *J. Pain Symptom Manage.* 13, 63–74. [https://doi.org/10.1016/S0885-3924\(96\)00274-6](https://doi.org/10.1016/S0885-3924(96)00274-6)